We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed the most recent trading day at $81.36, moving +2.56% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%.
Shares of the drugstore chain and pharmacy benefits manager have appreciated by 1.86% over the course of the past month, outperforming the Medical sector's gain of 0.92%, and the S&P 500's gain of 1.57%.
The investment community will be paying close attention to the earnings performance of CVS Health in its upcoming release. The company is slated to reveal its earnings on February 11, 2026. The company is forecasted to report an EPS of $0.99, showcasing a 16.81% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.03 billion, up 5.44% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.65 per share and revenue of $399.4 billion, which would represent changes of +22.69% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. CVS Health presently features a Zacks Rank of #3 (Hold).
With respect to valuation, CVS Health is currently being traded at a Forward P/E ratio of 11.1. This signifies a discount in comparison to the average Forward P/E of 15.53 for its industry.
Also, we should mention that CVS has a PEG ratio of 0.73. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.92.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 197, positioning it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CVS Health (CVS) Exceeds Market Returns: Some Facts to Consider
CVS Health (CVS - Free Report) closed the most recent trading day at $81.36, moving +2.56% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.26%. At the same time, the Dow added 0.6%, and the tech-heavy Nasdaq gained 0.25%.
Shares of the drugstore chain and pharmacy benefits manager have appreciated by 1.86% over the course of the past month, outperforming the Medical sector's gain of 0.92%, and the S&P 500's gain of 1.57%.
The investment community will be paying close attention to the earnings performance of CVS Health in its upcoming release. The company is slated to reveal its earnings on February 11, 2026. The company is forecasted to report an EPS of $0.99, showcasing a 16.81% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.03 billion, up 5.44% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $6.65 per share and revenue of $399.4 billion, which would represent changes of +22.69% and 0%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. CVS Health presently features a Zacks Rank of #3 (Hold).
With respect to valuation, CVS Health is currently being traded at a Forward P/E ratio of 11.1. This signifies a discount in comparison to the average Forward P/E of 15.53 for its industry.
Also, we should mention that CVS has a PEG ratio of 0.73. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Medical Services industry held an average PEG ratio of 1.92.
The Medical Services industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 197, positioning it in the bottom 20% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.